Actively Recruiting

Age: 0 - 18Years
All Genders
ID06007456

Clinical, Laboratory and Ultrasound Stratification of Patients With Juvenile Idiopathic Arthritis and Outcomes Evaluation During Transition to Adult Care

Led by IRCCS Burlo Garofolo · Updated on 2024-06-14

80

Participants Needed

2

Research Sites

78 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Juvenile Idiopathic Arthritis (JIA) is the most common chronic rheumatologic disease in children, defined by arthritis lasting at least six weeks without a known cause in patients under 16. This condition includes various diseases grouped under the current classification system, which may not accurately reflect the differences in disease types or severity. Researchers aim to improve classification using clinical, laboratory, and ultrasound data to personalize treatment and better understand disease biology, especially during transition from pediatric to adult care. This observational study follows patients with new or ongoing JIA to evaluate disease activity and joint damage as they transition to adult care. The study uses tools like musculoskeletal ultrasound to detect inflammation and patterns of joint involvement, which may guide treatment choices. Patients are grouped based on disease onset or follow-up status, and assessments include clinical and imaging evaluations. Participants will be monitored between ages 14 and 17, with evaluations including the Juvenile Arthritis Disease Activity Score, Health Assessment Questionnaire - Disability Index, and radiological exams to assess joint damage. The study also measures non-inflammatory pain using a widespread pain index scale. The goal is to track disease progression and outcomes during this critical transition period, providing detailed patient data over time to support personalized care strategies.

CONDITIONS

Brief Title

Clinical, Laboratory and Ultrasound Stratification of Patients With Juvenile Idiopathic Arthritis

Who Can Participate

Age: 0 - 18Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Subjects under the age of 18 years
  • Arthritis persisting for at least 6 weeks with no known cause
Not Eligible

You will not qualify if you...

  • No consent from the patients' guardians
  • Patients with Systemic onset Juvenile Idiopathic Arthritis
  • Patients who developed arthritis on a pre-existing inflammatory disorder such as Inflammatory Bowel Disease, and had received previous treatments

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Monitoring

Duration - Between 14 and 17 years of age

Participants are observed to evaluate disease activity, joint damage, and pain during the transition to adult care.

Periodic visits during the transition period

Trial Site Locations

Total: 2 locations

1

IRCCS Burlo Garofolo

Trieste, Italy, 34137

Actively Recruiting

2

(Department of Medical and Biological Sciences, Rheumatology Clinic, University of Udine

Udine, Italy

Actively Recruiting

Loading map...

Research Team

S

Serena Pastore, MD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

An Open-label, Sequential, Ascending, Repeated Dose-finding ...

Juvenile Idiopathic Arthritis

Actively Recruiting

32 locations

A Phase 3 Multicenter Study to Evaluate the Long-Term Safety...

Juvenile Idiopathic Arthritis

Actively Recruiting

80 locations

Conception of a Diagnosis, Prognosis and Therapeutic Decisio...

Autoimmune Lymphoproliferative Syndrome

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here